{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Toronto",
      "state": "",
      "country": "Canada",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "71999",
      "recalling_firm": "Apotex Inc.",
      "address_1": "150 Signet Drive",
      "address_2": "",
      "postal_code": "N/A",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "",
      "distribution_pattern": "Nationwide and Puerto Rico",
      "recall_number": "D-1814-2015",
      "product_description": "Cevimeline Hydrochloride Capsules, 30 mg  a) 100 count bottle, and b) 500 count bottle, Rx Only, Manufactured by: Apotex Research Pvt., Ltd., Bangalore, India, Manufactured for: Apotex Corp, Westin, FL, a) NDC 60505-3145-1, b) NDC 60505-3145-5",
      "product_quantity": "117,644 Bottles",
      "reason_for_recall": "Failed Stability Specifications: product may not meet specification limit for assay test.",
      "recall_initiation_date": "20150817",
      "center_classification_date": "20150915",
      "termination_date": "20220615",
      "report_date": "20150923",
      "code_info": "Lot #s: a) KP9749, KT3501, Exp 09/2015, KP4524, Exp 11/2015, KV8264, Exp 01/2016, KX8713, KX8714, KX8715, Exp 04/2016; b) KP4525, Exp 11/2015, KP9750, Exp 12/2015, KX8716, Exp 04/2016",
      "more_code_info": ""
    }
  ]
}